Market Indices
Sector Heatmap
LGND — Ligand Pharmaceuticals Inc.
NasdaqLigand Pharmaceuticals Inc.
- O
- 303.95
- H
- 309.77
- L
- 300.79
- V
- 162.77K
LGND — Latest News & Headlines
16 StoriesLigand Pharmaceuticals (LGND) Stock May Be 27% Undervalued After A New Royalty Deal - Yahoo Finance
Ligand Pharmaceuticals (LGND) Stock May Be 27% Undervalued After A New Royalty Deal Yahoo Finance
Ligand Pharmaceuticals (NASDAQ:LGND) Flashes Strong Trend and High-Growth Momentum Despite Setup Caution - ChartMill
Ligand Pharmaceuticals (NASDAQ:LGND) Flashes Strong Trend and High-Growth Momentum Despite Setup Caution ChartMill
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari Stocktwits
Ligand Pharma a new Outperform at Barclays on biopharma royalty aggregation (LGND:NASDAQ) - Seeking Alpha
Ligand Pharma a new Outperform at Barclays on biopharma royalty aggregation (LGND:NASDAQ) Seeking Alpha
How Investors Are Reacting To Ligand Pharmaceuticals (LGND) Ryjunea Royalty Rights Deal - Simply Wall Street
How Investors Are Reacting To Ligand Pharmaceuticals (LGND) Ryjunea Royalty Rights Deal Simply Wall Street
Liquidity Mapping Around (LGND) Price Events - Stock Traders Daily
Liquidity Mapping Around (LGND) Price Events Stock Traders Daily
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts Yahoo Finance
Barclays Initiates Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $345 - Moomoo
Barclays Initiates Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $345 Moomoo
StoneX updates its best ideas list - TradingView
StoneX updates its best ideas list TradingView
CAR T Funding Deal Could Be A Game Changer For Ligand Pharmaceuticals (LGND) - Simply Wall Street
CAR T Funding Deal Could Be A Game Changer For Ligand Pharmaceuticals (LGND) Simply Wall Street
Oppenheimer reiterates Ligand Pharma stock rating on AvenCell deal By Investing.com - Investing.com UK
Oppenheimer reiterates Ligand Pharma stock rating on AvenCell deal By Investing.com Investing.com UK
Ligand Pharmaceuticals stock expands royalty pipeline with USD 47.00 million deal - AD HOC NEWS
Ligand Pharmaceuticals stock expands royalty pipeline with USD 47.00 million deal AD HOC NEWS
Barclays Initiates Ligand Pharmaceuticals at Overweight With $345 Price Target - Yahoo Finance
Barclays Initiates Ligand Pharmaceuticals at Overweight With $345 Price Target Yahoo Finance
Ligand Pharmaceuticals (LGND) Faces A Valuation Test After Expanding Ryjunea Royalties - Simply Wall St
Ligand Pharmaceuticals (LGND) Faces A Valuation Test After Expanding Ryjunea Royalties Simply Wall St
Ligand Pharmaceuticals stock reports stronger royalty growth after Q2 results - AD HOC NEWS
Ligand Pharmaceuticals stock reports stronger royalty growth after Q2 results AD HOC NEWS
LGND Dec 2027 260.000 call (LGND271217C00260000) Interactive Stock Chart - Yahoo! Finance Canada
LGND Dec 2027 260.000 call (LGND271217C00260000) Interactive Stock Chart Yahoo! Finance Canada